NCT04515147View on ClinicalTrials.gov

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

668

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

February 21, 2022

Study Completion Date

February 21, 2022

Conditions
CoronavirusCovid19SARS-CoV-2Severe Acute Respiratory Syndrome
Interventions
BIOLOGICAL

CVnCoV 6 μg

Participants will receive an intramuscular injection by needle in the deltoid area.

BIOLOGICAL

CVnCoV 12 μg

Participants will receive an intramuscular injection by needle in the deltoid area.

BIOLOGICAL

Hepatitis A vaccine

Participants will receive an intramuscular injection by needle in the deltoid area.

BIOLOGICAL

Pneumococcal vaccine

Participants will receive an intramuscular injection by needle in the deltoid area.

BIOLOGICAL

CVnCoV 12μg

Participants will receive an intramuscular injection by needle in the deltoid area.

Trial Locations (2)

0831

Centro de vacunación internacional - CEVAXIN Panama Clinic, Panama City

Lima - 12

Instituto de Investigación Nutricional, Lima

Sponsors

Lead Sponsor

CureVac
All Listed Sponsors
collaborator

German Federal Ministry of Education and Research

OTHER_GOV

lead

CureVac

INDUSTRY